Vaccitech reports Q2 net income of $15.7M on $17.1M in Vaxzevria royalties

Barinthus Biotherapeutics plc.

2022-Q2 EPS reported $0.48 revenue$32,081,000

Net income $15.7M ($0.41 diluted EPS) vs $2.6M ($0.068) in Q1 2022.
Revenue $17.1M from milestone/royalty payments from AstraZeneca for Vaxzevria sales.
Cash $192.3M at June 30 vs $214.1M at Dec 31, 2021; $15.0M used in operations.
R&D expenses $9.7M (down from $10.7M); G&A excluding FX gain was $8.8M.
Clinical highlights: VTP-300 HBV data, EMA advice for MERS vaccine, HPV trial enrollment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.